AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

A federal jury in Delaware found that Revance's rival product infringed patents for Allergan's market-leading neurotoxin ...

A federal jury July 18 said Revance Therapeutics' skin medication infringed on patents for anti-wrinkle treatment Botox and owes AbbVie-owned Allergan $56 million.

Shares of Revance Therapeutics surged more than 16% on Monday morning, reaching over a month’s high, leading to a jump in retail chatter on Stocktwits. The surge followed a proposal from ...

Revance Therapeutics' share price has been characterised by volatility ever since its IPO. Learn why RVNC shares trade close to an all-time low today. Skip to content.

Crown Labs, which agreed to acquire Revance Therapeutics for $6.66 a share in cash last month, was expected to start a tender offer by a Friday deadline, according to an 8-K filing from Aug. 28 ...

Shares of Revance Therapeutics surged 18% Thursday after the company announced the Food and Drug Administration had approved Daxxify, a facial injection drug that Revance hopes will challenge ...

Revance Therapeutics, Inc. reported its Q4 and FY 23 earnings yesterday, February 28th - its stock price has been soaring as a result. The company is guiding for ~$280m of revenues in 2024 and ...

(RTTNews) - Revance Therapeutics, Inc. (RVNC) disclosed on Monday that it has entered into a merger agreement with Crown Laboratories, Inc., which plans to purchase all outstanding shares of ...